Skip to main content
Figure 1 | Virology Journal

Figure 1

From: A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

Figure 1

Seroreactive response of patients with cervical intraepithelial neoplasia grade 1 (CIN 1) and HPV-16 infection to various virus-like particles (VLPs). (A) IgG antibody responses to VLPs derived from: the commercial vaccine Gardasil® (gVLP, circles) containing HPV-16, -18, -6 and -11 serotypes; plant-based VLPs composed by HPV-16 L1 protein (VLP-L1, triangles); or chimeric particles containing the HPV-16 L1 sequence and sequences encoding E6 and E7 known antigenic peptides fused to the C-terminus (cVLP, squares), were determined in sera from women with no evidence of HPV infection (normal, open symbols), and in sera from patients with CIN 1 and HPV-16 infection (HPV-16, filled symbols). Results are divided into two specific groups of titers: a high-titer group (H) and a low-titer group (L). The mean absorbance distribution of each group is represented by a solid line. Values of the mean absorbance distribution of the H and L groups are indicated by arrows. (B) Shown are the mean absorbance distribution of the control positive group and the cut-off values for high seroreactivity at A 405 (indicated by horizontal dashed lines and numbers) in response to gVLP (gray circles), VLP-L1 (gray triangles), and cVLP (gray squares). *Indicates difference between groups is statistically significant. P-values were calculated using Wilcoxon signed-rank test and Student's t-test.

Back to article page